Lycopodium japonicum Thunb. inhibits chondrocyte apoptosis, senescence and inflammation in osteoarthritis through STING/NF-κB κ B signaling pathway

被引:0
|
作者
Ma, Jiawei [1 ,2 ,3 ]
Zhang, Hanwen [1 ,2 ,3 ]
Wang, Ze [1 ,2 ,3 ]
Xu, Cong [1 ]
Tan, Hongye [1 ,2 ,3 ]
Sun, Yun [1 ,2 ,3 ]
Zheng, Rukang [1 ,2 ,3 ]
Jin, Zebin [1 ,2 ,3 ]
Li, Yuanyuan [4 ]
Ge, Xinjiang [4 ]
Wu, Yaosen [1 ]
Zhou, Yifei [1 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China
[2] Zhejiang Prov Key Lab Orthoped, Wenzhou, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Sch Med 2, Wenzhou, Zhejiang, Peoples R China
[4] First Peoples Hosp Aksu Reg, Dept Neurosurg, Aksu, Xinjiang, Peoples R China
关键词
Osteoarthritis; STING; Lycopodium japonicum thunb; Inflammatory; Senescence; Apoptosis; 2ND-MESSENGER;
D O I
10.1016/j.jep.2024.118660
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Osteoarthritis (OA) is a degenerative disease, its characteristic lies in the inflammation and extracellular matrix (ECM) degradation, can lead to significant personal disability and social burden. Lycopodium japonicum Thunb. (LJT) is a lycopinaceae plant with anti-inflammatory and analgesic effects. In traditional Oriental medicine, LJT is commonly used to treat a variety of conditions, including osteoarthritis and low back pain. Aim of the study: To investigate the anti-apoptotic, anti-inflammatory and anti-senescence properties of LJT in IL- 1(3-induced mouse chondrocytes, and to clarify the underlying mechanisms involved. In addition, the study also examined the effects of LJT by establishing a mouse model of osteoarthritis. The ultimate goal is to identify the mechanism of LJT as an anti-osteoarthritis agent. Materials and methods: In this research, molecular docking and network pharmacology analysis were performed to identify the latent pathways and key targets of LJT action. The CCK-8 kit was used to evaluate LJT's effect on chondrocyte viability. Western blotting, Immunofluorescence, TUNEL staining kit, and SA-(3-gal staining were employed to verify LJT's impact on chondrocytes. Additionally, SO, HE, and Immunohistochemical were utilized to assess LJT's effects on osteoarthritis in mice. In vitro and in vivo experiments were performed to verify the potential mechanism of LJT in OA. Results: Network pharmacology analysis revealed that AKT1, PTGS2, and ESR1 were the key candidate targets for the treatment of OA with LJT. The results of molecular docking indicated that AKT1 exhibited a low binding affinity to the principal constituents of LJT. Hence, we have chosen STING, an upstream regulator of PTGS2, as our target for investigation. Molecular docking revealed that sitosterol, formononetin, stigmasterol and alphaOnocerin, the main components of LJT, have good binding activity with STING. In vitro experiments showed that LJT inhibited IL-1(3-mediated secretion of inflammatory mediators, apoptosis and senescence of chondrocytes. The results showed that LJT abolished cartilage degeneration induced by unstable medial meniscus (DMM) in mice. Mechanism research has shown that LJT by inhibiting the STING/NF-kappa B signaling pathways, down-regulating the NF-kappa B activation, so as to inhibit the development of OA. Conclusion: LJT reversed the progression of OA by inhibiting inflammation, apoptosis and senescence in animal models and chondrocytes. The effects of LJT are mediated through the STING/NF-kappa B pathway.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Thymoquinone Inhibits IL-1β-Induced Inflammation in Human Osteoarthritis Chondrocytes by Suppressing NF-κB and MAPKs Signaling Pathway
    Wang, Dongyan
    Qiao, Jiutao
    Zhao, Xin
    Chen, Tianxin
    Guan, Dehong
    INFLAMMATION, 2015, 38 (06) : 2235 - 2241
  • [42] Yohimbine Ameliorates Temporomandibular Joint Chondrocyte Inflammation with Suppression of NF-κB Pathway
    Farong Ou
    Yihuan Huang
    Jiadong Sun
    Kai Su
    Yiqing He
    Rongsheng Zeng
    Dongxiao Tang
    Guiqing Liao
    Inflammation, 2021, 44 : 80 - 90
  • [43] Scoparone inhibits breast cancer cell viability through the NF-κB signaling pathway
    Wu, Xiaoying
    Li, Xiaobo
    Li, Jing
    Zhao, Xinrui
    Cui, Yongyuan
    Eerdun, Chaolu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (01)
  • [44] Yohimbine Ameliorates Temporomandibular Joint Chondrocyte Inflammation with Suppression of NF-κB Pathway
    Ou, Farong
    Huang, Yihuan
    Sun, Jiadong
    Su, Kai
    He, Yiqing
    Zeng, Rongsheng
    Tang, Dongxiao
    Liao, Guiqing
    INFLAMMATION, 2021, 44 (01) : 80 - 90
  • [45] Morin Inhibits Ovarian Cancer Growth through the Inhibition of NF-κB Signaling Pathway
    Xu, Meimei
    Zhang, Yan
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (18) : 2243 - 2250
  • [46] Phenobarbital inhibits osteoclast differentiation and function through NF-κB and MAPKs signaling pathway
    Wang, Wei
    Gao, Yuan
    Zheng, Wenwen
    Li, Minqi
    Zheng, Xuexing
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 69 : 118 - 125
  • [47] Morin inhibits colorectal tumor growth through inhibition of NF-κB signaling pathway
    Chen, Rui
    Zhang, Li
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2019, 41 (06) : 622 - 629
  • [48] Dihydromyricetin Inhibits Pseudorabies Virus Multiplication In Vitro by Regulating NF-κB Signaling Pathway and Apoptosis
    Zhao, Xufan
    Chen, Yaqin
    Zhang, Wenrui
    Zhang, Hui
    Hu, Yilong
    Yang, Fengyu
    Zhang, Yingying
    Song, Xu
    VETERINARY SCIENCES, 2023, 10 (02)
  • [49] Simvastatin induces apoptosis of nasopharyngeal carcinoma cells through NF-κB signaling pathway
    Sun, F-R
    Wang, S-L
    Wang, M.
    Sun, L-M
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (12) : 6726 - 6734
  • [50] Erythromycin inhibits cigarette smoke-induced inflammation through regulating the PPARγ/NF-κB signaling pathway in macrophages
    Qiu, Ju-Feng
    Ma, Nan
    He, Zhi-Yi
    Zhong, Xiao-Ning
    Zhang, Jian-Quan
    Bai, Jing
    Deng, Jing-Min
    Tang, Xiao-Juan
    Luo, Zhou-Ling
    Huang, Mei
    Liang, Quan
    Wei, Yan-Ling
    Tang, Ming-Jiao
    Li, Mei-Hua
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 96